Holding(s) in Company
22 2월 2008 - 1:27AM
UK Regulatory
RNS Number:5114O
EiRx Therapeutics PLC
21 February 2008
TR-1: Notifications of Major Interests in Shares
1. Identity of the issuer or the underlying issuer of
existing shares to which voting rights are attached:
Eirx Therapeutics Plc
2. Reason for notification (yes/no)
An acquisition or disposal of voting rights YES
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached NO
An event changing the breakdown of voting rights NO
Other (please specify):______________ NO
3. Full name of person(s) subject to notification
obligation:
Barclays PLC
4. Full name of shareholder(s) (if different from
3):
Barclays Stockbrokers Ltd
5. Date of transaction (and date on which the
threshold is crossed or reached if different):
19 February 2008
6. Date on which issuer notified:
20 February 2008
7. Threshold(s) that is/are crossed or reached:
6% to 7%
8. Notified details:
N/A
A: Voting rights attached to shares
Class/type of Situation previous to the Resulting situation after the triggering transaction
shares triggering transaction
Number of Number of Number of Number of voting rights Percentage of voting
If possible use shares voting shares rights
ISIN code rights
Direct Direct Indirect Direct Indirect
GB00B0XQBS97 187,968,924 187,968,924 211,630,528 0 211,630,528 0.00 7.11
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial Expiration date Exercise/ conversion No. of voting rights Percentage of voting
instrument period/date that may be acquired rights
(if the instrument
exercised/converted)
N/A N/A N/A N/A N/A
Total (A+B)
Number of voting rights Percentage of voting rights
211,630,528 7.11
9. Chain of controlled undertakings through which the voting rights and /or the
financial instruments are effectively held, if applicable:
Barclays Stockbrokers Ltd
Proxy Voting:
10. Name of proxy holder: N/A
11. Number of voting rights proxy holder will cease N/A
to hold:
12. Date on which proxy holder will cease to hold N/A
voting rights:
13. Additional information: N/A
14 Contact name: Geoff Smith
15. Contact telephone name: 0207 116 2913
For notes on how to complete form TR-1 please see the FSA website.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUAUNRWSRUUAR
Eirx Therapeutics (LSE:ERX)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Eirx Therapeutics (LSE:ERX)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024
Eirx Therap. (런던증권거래소)의 실시간 뉴스: 최근 기사 0
More Eirx Therapeutic Plc News Articles